PTPI - Petros Pharmaceuticals, Inc. Stock Price, Fair Value and News

0.59USD+0.04 (+7.27%)Delayed as of 17 May 2024, 02:06 pm ET

Market Summary

USD0.59+0.04

Delayedas of 17 May 2024, 02:06 pm

7.27%

PTPI Stock Price

View Fullscreen

PTPI RSI Chart

PTPI Valuation

Market Cap

3.9M

Price/Earnings (Trailing)

-0.43

Price/Sales (Trailing)

0.66

EV/EBITDA

1.81

Price/Free Cashflow

-0.48

PTPI Price/Sales (Trailing)

PTPI Profitability

EBT Margin

-133.61%

Return on Equity

-91.36%

Return on Assets

-29.5%

Free Cashflow Yield

-208.12%

PTPI Fundamentals

PTPI Revenue

Revenue (TTM)

5.8M

Rev. Growth (Yr)

-44.84%

Rev. Growth (Qtr)

-9.33%

PTPI Earnings

Earnings (TTM)

-8.9M

Earnings Growth (Yr)

-56.13%

Earnings Growth (Qtr)

-779.76%

Breaking Down PTPI Revenue

52 Week Range

0.554.74

(Low)(High)

Last 7 days

-12.5%

Last 30 days

-20%

Last 90 days

-62.7%

Trailing 12 Months

-87.6%

How does PTPI drawdown profile look like?

PTPI Financial Health

Current Ratio

1.6

PTPI Investor Care

Shares Dilution (1Y)

231.20%

Diluted EPS (TTM)

-7.38

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	6.3M	6.7M	7.0M	5.8M
2022	7.4M	6.9M	6.4M	6.0M
2021	11.8M	12.9M	11.6M	7.8M
2020	14.1M	12.6M	11.1M	9.6M
2019	0	0	0	15.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Petros Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 21, 2023	boctor fady	acquired	-	-	49,645	see remarks
Apr 26, 2023	bradley greg	acquired	-	-	6,050	-
Apr 26, 2023	bernstein bruce	acquired	-	-	6,050	-
Apr 26, 2023	silverman joshua	acquired	-	-	6,722	-
Apr 26, 2023	walker wayne remell	acquired	-	-	6,050	-
Jan 20, 2023	walker wayne remell	acquired	-	-	2,264	-
Jan 20, 2023	bradley greg	acquired	-	-	2,264	-
Jan 20, 2023	bernstein bruce	acquired	-	-	2,264	-
Jan 20, 2023	silverman joshua	acquired	-	-	2,515	-
Dec 22, 2021	shulman john d	bought	500,001	3.43	145,773	-

Which funds bought or sold PTPI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	added	2,578	726	753	-%
May 15, 2024	FIRST MANHATTAN CO. LLC.	sold off	-100	-14.00	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-	1.00	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	sold off	-100	-31,866	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-62.8	-7,844	5,025	-%
May 14, 2024	1832 Asset Management L.P.	unchanged	-	1.00	15.00	-%
May 13, 2024	NATIONAL BANK OF CANADA /FI/	new	-	198	198	-%
May 13, 2024	FMR LLC	sold off	-100	-28.00	-	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	630	15,542	-%
May 10, 2024	GROUP ONE TRADING, L.P.	unchanged	-	5.00	117	-%

Are Funds Buying or Selling PTPI?

Are funds buying PTPI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PTPI

No. of Funds

Unveiling Petros Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ayrton capital llc	9.9%	244,291	SC 13G
Feb 06, 2024	intracoastal capital, llc	6.6%	154,768	SC 13G/A
Feb 08, 2023	intracoastal capital, llc	7.6%	167,139	SC 13G/A
Feb 28, 2022	shulman john d	0.06%	13,648	SC 13D/A
Feb 23, 2022	iroquois capital management, llc	4.18%	103,474	SC 13G/A
Feb 11, 2022	intracoastal capital, llc	7.2%	1,601,666	SC 13G/A

Recent SEC filings of Petros Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 03, 2024	S-3	S-3
Apr 01, 2024	10-K	Annual Report
Mar 22, 2024	8-K	Current Report
Feb 14, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Petros Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	371.3B	85.6B	6.80%	-2.97%	9.65	4.33	5.68%	202.39%
MRK	331.6B	61.4B	4.69%	14.08%	143.8	5.4	6.11%	-82.30%
AMGN	168.9B	29.5B	18.50%	39.89%	44.87	5.72	12.76%	-52.47%
PFE	163.9B	57.8B	12.61%	-21.28%	130.78	2.84	76.51%	-86.81%
GILD	84.6B	27.4B	0.85%	-13.87%	174.55	3.08	1.51%	-91.32%
TEVA	18.5B	16.0B	24.52%	100.49%	-37.33	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	2.99%	-21.03%	9.53	2.4	54.01%	364.56%
PRGO	4.1B	4.6B	0.47%	-8.40%	-532.89	0.9	-0.06%	94.55%
BHC	2.6B	9.0B	-19.11%	-5.35%	-5.7	0.29	10.01%	-27.45%
AMPH	2.1B	676.2M	4.47%	-0.56%	13.51	3.09	30.38%	66.04%
SMALL-CAP
TLRY	1.6B	743.2M	16.39%	-11.62%	-4.68	2.22	24.65%	80.36%
TXMD	24.2M	1.3M	10.53%	-49.88%	-3.27	18.6	-98.14%	-104.71%
ACRX	19.7M	89.6M	13.73%	58.80%	-1.39	0.19	287.27%	-129.41%
AGRX	2.6M	21.5M	2.56%	-90.89%	-0.34	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Petros Pharmaceuticals, Inc. News

Latest updates

Petros Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-9.3%	1,388,806	1,531,732	1,674,657	1,994,011	2,517,972	798,101	2,492,309	4,186,516	2,465,169	2,305,169	2,145,169	2,457,649	4,075,606	2,929,289	3,464,695	1,373,564	1,791,921	-
Gross Profit	302.3%	1,056,975	-522,397	1,266,182	1,480,154	1,967,230	-83,231	-1,744,257	3,537,296	1,992,829	-1,110,888	1,826,011	2,064,355	3,432,220	1,187,992	2,482,792	834,333	1,007,886	-
Operating Expenses	10.4%	4,985,248	4,516,221	6,072,823	3,942,962	3,276,527	4,017,881	11,927,761	5,198,716	2,474,027	6,862,312	5,422,628	6,345,047	5,629,727	5,505,978	4,819,213	5,852,641	6,617,210	-
S&GA Expenses	-5.8%	2,711,456	2,879,305	2,001,935	2,249,592	2,130,639	2,923,845	2,170,975	3,216,604	3,897,738	4,182,120	3,413,223	4,116,173	3,881,717	3,677,784	3,121,023	4,059,698	4,816,463	-
R&D Expenses	86.5%	1,555,953	834,334	389,093	866,575	319,093	177,762	735,916	421,242	405,360	988,688	280,576	500,046	19,181	151,840	36,828	131,583	139,385	-
EBITDA Margin	35.3%	-0.69	-1.06	-3.00	-2.61	-2.59	-3.75	-2.90	-0.99	-0.25	-0.22	-0.01	-0.12	-0.44	-1.48	-	-	-	-
Interest Expenses	-56.2%	151,819	346,830	168,481	-52,924	-66,317	-436,881	298,049	-	-	28,244	84,080	132,820	176,677	238,229	270,053	311,058	372,060	-
Income Taxes	-	-	-	-	-	-	-	10,501	-	-	-9,045	2,345	6,700	-	-1,377,098	-6,143	-13,781	-29,971	-
Earnings Before Taxes	-779.8%	-2,162,663	318,150	-4,549,508	-	-1,385,147	-4,231,861	-13,819,695	-1,811,792	-	-8,194,987	-1,694,553	-2,106,217	3,009,081	-6,815,070	-3,306,506	-5,778,152	-6,113,190	-
EBT Margin	21.0%	-1.34	-1.69	-3.43	-3.19	-3.36	-4.68	-3.96	-2.00	-1.22	-1.15	-0.66	-0.71	-1.09	-2.30	-	-	-	-
Net Income	-779.8%	-2,162,663	318,150	-4,549,508	-2,546,683	-1,385,147	-4,221,360	-13,830,196	-1,811,792	-174,224	-8,185,942	-1,696,898	-2,112,917	3,009,081	-5,437,972	-3,300,363	-5,764,371	-6,083,219	-
Net Income Margin	-9.5%	-1.54	-1.40	-1.82	-3.30	-3.36	-3.34	-3.72	-1.72	-1.65	-1.15	-0.54	-0.61	-0.97	-2.15	-	-	-	-
Free Cashflow	49.8%	-1,134,848	-2,259,894	-4,046,202	-572,070	-748,363	-1,570,340	-1,751,476	-4,199,808	-5,275,701	-8,304,299	-1,211,366	-1,899,785	-446,581	-4,522,895	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-10.3%	30.00	34.00	39.00	29.00	31.00	32.00	38.00	51.00	56.00	67.00	52.00	57.00	66.00	70.00	58.00
Current Assets	-12.2%	18.00	20.00	24.00	13.00	14.00	15.00	19.00	23.00	27.00	31.00	13.00	16.00	24.00	26.00	12.00
Cash Equivalents	-16.9%	11.00	13.00	18.00	7.00	8.00	9.00	11.00	13.00	18.00	24.00	8.00	11.00	15.00	17.00	2.00
Inventory	-3.3%	2.00	2.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	0.00	1.00	1.00	2.00
Net PPE	-8.8%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-8.0%	20.00	21.00	32.00	16.00	15.00	16.00	17.00	17.00	20.00	32.00	34.00	37.00	45.00	52.00	50.00
Current Liabilities	4.2%	11.00	11.00	8.00	8.00	7.00	7.00	8.00	7.00	10.00	31.00	34.00	34.00	40.00	42.00	41.00
Shareholder's Equity	-18.9%	10.00	12.00	7.00	13.00	15.00	17.00	21.00	34.00	36.00	36.00	18.00	19.00	21.00	17.00	8.00
Retained Earnings	-2.2%	-101	-98.90	-99.20	-94.70	-92.10	-90.73	-86.51	-72.67	-70.90	-70.69	-62.50	-60.81	-58.69	-61.70	-41.12
Additional Paid-In Capital	-0.1%	111	111	106	108	108	107	107	107	107	106	80.00	80.00	80.00	79.00	-
Shares Outstanding	129.9%	7.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	-
Float	-	-	-	-	3.00	-	-	-	13.00	-	-	-	20.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	49.8%	-1,134	-2,259	-4,046	-572	-748	-1,570	-1,751	-4,199	-5,275	-8,304	-1,211	-1,899	-446	-4,522	-2,667	-5,740	-2,375	-
Share Based Compensation	-	-	-	-	-	130	-	-	302	356	126	53.00	591	347	-	-	-	-	-
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-204*	-	-4.43	-
Cashflow From Financing	52.7%	-1,121	-2,373	14,631	-363	-357	-185	-361	-176	-900	24,017	-1,684	-1,635	-2,126	20,994	2,505	5,430	1,376	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PTPI Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Net sales	$ 1,388,806	$ 2,517,972
Cost of goods sold	331,831	550,742
Gross profit	1,056,975	1,967,230
Operating expenses:
Selling, general and administrative	2,711,456	2,130,639
Research and development expense	1,555,953	319,093
Depreciation and amortization expense	717,839	826,795
Total operating expenses	4,985,248	3,276,527
Loss from operations	(3,928,273)	(1,309,297)
Other income (expenses):
Change in fair value of derivative liability	1,734,000
Interest income	151,819	66,317
Interest expense, promissory note	120,209	142,167
Total other income (expenses)	1,765,610	(75,850)
Net loss before income taxes	(2,162,663)	(1,385,147)
Net loss	(2,162,663)	(1,385,147)
Preferred Stock dividend and cash premiums	(595,505)
Preferred Stock accretion	(5,268,776)
Net loss attributable to common stockholders	$ (8,026,944)	$ (1,385,147)
Net loss per common share
Basic (in dollars per share)	$ (1.69)	$ (0.66)
Diluted (in dollars per share)	$ (1.69)	$ (0.66)
Weighted average common shares outstanding
Basic (in shares)	4,756,952	2,088,698
Diluted (in shares)	4,756,952	2,088,698

PTPI Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 11,080,716	$ 13,336,975
Accounts receivable, net	1,957,005	2,226,151
Inventories	1,557,018	1,610,391
Prepaid inventory	1,182,899	1,182,899
Prepaid expenses and other current assets	2,124,817	2,033,980
Total current assets	17,902,455	20,390,396
Fixed assets, net	26,402	28,957
Intangible assets, net	8,256,453	8,971,737
API purchase commitment	3,936,454	4,178,446
Right of use assets	190,571	226,259
Total assets	30,312,335	33,795,795
Current liabilities:
Current portion of promissory note	1,553,689	1,156,550
Accounts payable	2,137,255	1,713,253
Accrued expenses	6,326,001	5,360,077
Accrued Series A Convertible Preferred payments payable	840,353	2,047,583
Other current liabilities	362,233	493,288
Total current liabilities	11,219,531	10,770,751
Promissory note, net of current portion	6,460,225	6,857,364
Derivative Liability	1,816,000	3,550,000
Other long-term liabilities	123,021	137,657
Total liabilities	19,618,777	21,315,772
Commitments and contingencies (see note 14)
Series A convertible redeemable preferred stock (par value $0.0001 per share and $1,000 stated value), 15,000 and 15,000 shares authorized at March 31, 2024, and December 31, 2023, respectively; 5,663 and 10,022 shares issued and outstanding at March 31, 2024, and December 31, 2023, respectively; Liquidation preference of $6,387,083 and $11,271,365, as of March 31, 2024, and December 31, 2023, respectively.	906,979	408,982
Stockholders' Equity:
Common stock (par value $0.0001 per share, 250,000,000 and 250,000,000 shares authorized at March 31, 2024, and December 31, 2023, respectively; 6,881,864 and 2,991,377 shares issued and outstanding as of March 31, 2024, and December 31, 2023, respectively)	688	298
Additional paid-in capital	110,838,135	110,960,324
Accumulated deficit	(101,052,244)	(98,889,581)
Total Stockholders' Equity	9,786,579	12,071,041
Total Liabilities, Convertible Redeemable Preferred Stock and Stockholders' Equity	$ 30,312,335	$ 33,795,795

About Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

WEBSITE	petrospharma.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	24

Petros Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Petros Pharmaceuticals, Inc.? What does PTPI stand for in stocks?

PTPI is the stock ticker symbol of Petros Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Petros Pharmaceuticals, Inc. (PTPI)?

As of Thu May 16 2024, market cap of Petros Pharmaceuticals, Inc. is 3.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTPI stock?

You can check PTPI's fair value in chart for subscribers.

What is the fair value of PTPI stock?

You can check PTPI's fair value in chart for subscribers. The fair value of Petros Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Petros Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PTPI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Petros Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether PTPI is over valued or under valued. Whether Petros Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Petros Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTPI.

What is Petros Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, PTPI's PE ratio (Price to Earnings) is -0.43 and Price to Sales (PS) ratio is 0.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTPI PE ratio will change depending on the future growth rate expectations of investors.